Summary
Pharma API and CRAMS firms experienced a significant acceleration in profit after tax (PAT) growth during Q1 FY27, with the median rising to 47% from 8% in the previous quarter. This surge is attributed to contributions from CDMO projects, capacity expansions, and new product launches.